FDA on DSHEA
This article was originally published in The Tan Sheet
Executive Summary
Consumers are increasingly looking at scientific data to determine whether a product is safe and effective, making the Dietary Supplement Health & Education Act "a total aberration" since it does not require supplements undergo large-scale clinical trials prior to their marketing, FDA Office of Drug Evaluation I Director Robert Temple, MD, stated at the FDLI educational conference in Washington, D.C. Dec. 16. Attorney Stephen McNamara (Hyman, Phelps & McNamara) disagreed, however, noting science is not always the overriding factor, but that consumer demand itself, a legitimate concern, can dictate policy as well. To illustrate his point, McNamara referred to consumers' desire for diet beverages, which outweighed FDA concerns over the safety of saccharine
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning